# ADMA Biologics Inc

> Clarifo company profile — qualitative business description generated from
> the company's filings. Financial statements, charts and ratios are
> available on Clarifo (https://www.clarifo.com/en/companies/ADMA Biologics Inc).

## Overview

ADMA Biologics, Inc. is a U.S.-based commercial biopharmaceutical company that manufactures, markets, and develops plasma-derived specialty biologics used to treat immunodeficient and other immune-compromised patients at risk for serious infections. The company operates an end-to-end model that combines FDA-licensed plasma collection centers with an FDA-licensed plasma fractionation and purification manufacturing facility in Boca Raton, Florida. ADMA’s commercial portfolio is centered on immune globulin (IG) products, including ASCENIV and BIVIGAM, and it also sells plasma and other intermediates when not used internally. The business is organized around two segments: ADMA BioManufacturing (finished IG products and related activities) and Plasma Collection Centers (plasma sourcing and third-party plasma sales).

## Products & services

• ASCENIV (immune globulin) for immunodeficient patients
• BIVIGAM (immune globulin)
• Nabi-HB (Hepatitis B immune globulin; within intermediates)
• Normal source & hyperimmune plasma sales to third parties
• Contract manufacturing (fill-finish, labeling, packing)
• Laboratory testing services (incl. proprietary RSV assay access)
• Plasma collection operations (10 FDA-licensed centers)

- **ASCENIV (IG product)** (56%) — Sales of ASCENIV immune globulin product manufactured and commercialized by ADMA.
- **BIVIGAM (IG product)** (33%) — Sales of BIVIGAM immune globulin product manufactured and commercialized by ADMA.
- **Intermediates and other products** (8%) — Includes intermediates, other product sales and items such as Nabi-HB historically under 10% of revenue.
- **Plasma Collection Centers (third-party plasma sales)** (3%) — Sales of normal source plasma and hyperimmune plasma not used internally, sold via supply agreements or spot market.

- ASCENIV (immune globulin) for immunodeficient patients
- BIVIGAM (immune globulin)
- Nabi-HB (Hepatitis B immune globulin; within intermediates)
- Normal source & hyperimmune plasma sales to third parties
- Contract manufacturing (fill-finish, labeling, packing)
- Laboratory testing services (incl. proprietary RSV assay access)
- Plasma collection operations (10 FDA-licensed centers)

## Customers

ADMA’s primary customers are U.S. pharmaceutical distributors and specialty distributors that purchase its immune globulin products for downstream delivery to hospitals, infusion centers, and clinicians treating primary immune deficiency and other immune-compromised patients. Customer concentration is high: in 2025, two customers (BioCare and Priority Healthcare Distribution/CuraScript) represented about 73% of consolidated revenue, making distributor relationships and purchasing patterns critical to near-term results. In addition to finished drug products, ADMA sells certain quantities of normal source plasma and hyperimmune plasma to third-party manufacturers when that plasma is not required for its own production plans. The company also provides contract manufacturing and laboratory services to select third parties, which can diversify revenue but depends on capacity availability and regulatory compliance.

- **U.S. pharmaceutical and specialty distributors (IG products)** (primary) — Purchase ASCENIV and BIVIGAM for distribution into immunology and infectious disease care settings; value reliable supply, reimbursement access, and product acceptance by physicians/payers.
- **Plasma-derived product manufacturers (plasma buyers)** (secondary) — Buy normal source plasma and hyperimmune plasma that ADMA collects but does not allocate to internal manufacturing; purchase decisions depend on plasma specifications and market pricing.
- **Contract services customers (manufacturing and lab services)** (emerging) — Select third parties purchasing contract manufacturing (fill-finish, labeling, packing) and laboratory services when ADMA has available capacity and required regulatory approvals.

- U.S. specialty distributors buying ASCENIV/BIVIGAM for patient access
- Large distributors (e.g., BioCare, CuraScript) drive volume and terms
- Clinics/hospitals indirectly served via distributor channel
- Third-party plasma fractionators buying excess source/hyperimmune plasma
- Biopharma clients purchasing contract fill-finish/packaging services
- Customers needing lab testing services (incl. RSV assay access via license)

## Geography

ADMA’s operations are primarily U.S.-based, with manufacturing conducted at its FDA-licensed plasma fractionation and purification facility in Boca Raton, Florida. The company’s plasma sourcing footprint includes ten FDA-licensed source plasma collection centers across the United States, which supply raw plasma for internal production and also support third-party plasma sales. While the core commercial focus is the U.S. market, ADMA has an ex-U.S. economic interest through a license with Biotest AG for ASCENIV commercialization in Europe and certain countries in Northern Africa and the Middle East, structured as royalties over a 20-year period from first commercial sale in the territory. Geographic exposure matters mainly through U.S. regulatory oversight (FDA inspections), domestic plasma availability, and the logistics of cold-chain storage and inventory given a long production cycle time.

- Manufacturing at FDA-licensed Boca Raton, Florida fractionation facility
- Ten FDA-licensed plasma collection centers across the United States
- Some centers also approved by Korea MFDS (enables certain plasma programs)
- Third-party plasma sales can include U.S. and approved ex-U.S. locations
- ASCENIV licensed to Biotest for Europe + parts of N. Africa/Middle East
- Cold-chain storage and long cycle times increase U.S. logistics importance

## Strategy

ADMA’s strategy emphasizes scaling its immune globulin franchise by increasing physician, payer, and patient adoption—particularly for ASCENIV—while ensuring adequate plasma supply and manufacturing throughput. A key operational priority is capacity and supply-chain enhancement at the Boca Raton facility (peak annual processing capability up to 600,000 liters) and building inventory to support a 7–12 month end-to-end production cycle. The company is also investing in infrastructure (IT, laboratory equipment, assays, and engineering) and has deployed an AI tool (ADMAlytics) to improve plasma pool composition and manufacturing efficiencies, aiming to reduce bottlenecks and improve yields. In parallel, management states it continues to evaluate strategic alternatives and other value-creating opportunities, which could include partnerships, licensing, or other corporate actions.

- **Increase commercial demand for ASCENIV and broader IG portfolio** (short-term) — Higher utilization improves scale benefits and supports manufacturing planning for long cycle-time products.
- **Expand and add redundancy to manufacturing and storage footprint** (medium-term) — Plasma-derived biologics require substantial inventories and cold-chain handling; added space reduces operational risk and supports growth.
- **Operational efficiency via data/AI-enabled process improvements** (medium-term) — Yield and throughput improvements can increase effective capacity and reduce cost per gram in a regulated manufacturing environment.

- Drive ASCENIV utilization via physician/payer/patient acceptance
- Expand and de-risk manufacturing and cold-chain storage in Boca Raton
- Secure adequate FDA-approved source and high-titer plasma supply
- Use ADMAlytics AI to improve plasma pool composition and efficiencies
- Maintain compliance readiness for FDA and other regulatory inspections
- Evaluate strategic alternatives and value-creating opportunities

## Risks

ADMA’s business is exposed to plasma supply and manufacturing execution risk: if it cannot obtain adequate FDA-approved source and high-titer plasma, or if plasma is damaged/contaminated, production and product availability can be disrupted. Regulatory risk is significant because both segments and key facilities are subject to periodic FDA inspections, and adverse findings could restrict operations or delay releases. Commercially, revenue concentration with a small number of distributors increases exposure to purchasing behavior, contract terms, and channel inventory dynamics. The company also faces cybersecurity and privacy compliance risk due to donor data collected at plasma centers, and it has additional risk from reliance on third parties for certain filling/packaging/testing activities. More broadly, the plasma products market is highly competitive, and new infectious disease outbreaks or precautionary public health measures could impair plasma procurement and manufacturing continuity.

- **Inability to obtain adequate quantities of FDA-approved source and high-titer plasma** [high] — Plasma is the critical raw material for IG products; shortages directly constrain manufacturing volumes and revenue.
- **Regulatory actions following FDA inspections of facilities and operations** [high] — Observations, warning letters, or enforcement actions can restrict manufacturing, delay releases, or require costly remediation.
- **Cyberattacks and security breaches** [medium] — Could compromise proprietary/confidential information, disrupt operations, and damage reputation in a regulated environment.
- **Consumer and health privacy law exposure from donor information collection** [medium] — Non-compliance can lead to enforcement actions and litigation, increasing costs and operational constraints.
- **AI tool (ADMAlytics) performance, bias, or integration failures** [medium] — Inaccurate outputs or system errors could impair decision-making in a highly regulated manufacturing environment and create liability/reputational harm.

- Plasma supply constraints (FDA-approved, high-titer) can limit output
- Plasma contamination/storage failures can force destruction of inventory
- FDA inspection outcomes could trigger warning letters or restrictions
- High customer concentration with distributors increases revenue volatility
- Reliance on third parties for fill/packaging/testing can cause delays
- Cybersecurity breaches could expose proprietary data and disrupt ops
- Donor privacy law compliance failures can create enforcement exposure
- Competitive pressure from larger plasma product producers

## Accounting

ADMA’s reported net revenues are sensitive to estimates for rebates, chargebacks, distribution fees, and sales allowances, which are recorded as deductions from gross product revenues in the same period revenue is recognized. These estimates can be complex and may require significant judgment, and changes in assumptions can create quarter-to-quarter volatility; the company cited a Medicaid rebate accrual adjustment recorded in 2024 that increased net revenues. The effective tax rate is another critical estimate area, with potential volatility tied to changes in taxable income mix, discrete items, and the realizability of deferred tax assets. Investors should also consider the working-capital and inventory implications of plasma-derived biologics manufacturing, where the end-to-end production cycle from raw material procurement to commercial release can take 7–12 months or longer, affecting inventory levels and cost absorption. Finally, amortization of intangibles is present (though not necessarily large), and its trajectory depends on the carrying values and useful lives assigned to acquired/recognized intangible assets.

- **Revenue deductions for rebates and chargebacks** — Impacts net product revenue, gross margin, and period comparability
- **Effective tax rate and deferred tax asset realizability (including NOL limitations)** — Impacts provision for income taxes and net income volatility

- Net revenue depends on estimates for rebates, chargebacks, and fees
- Changes in rebate accruals (e.g., Medicaid) can swing net revenues
- Effective tax rate estimates can create earnings volatility
- Long 7–12 month production cycle drives inventory and cost timing
- Judgment in provisions/estimates can cause period-to-period variability
- Intangible amortization affects operating expense comparability

---

*Last updated: 2026-09-24T11:32:33.600393+00:00*